ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen Says Recent Sensipar Study Failed to Meet Primary Endpoint

By Mia Lamar Amgen Inc. (AMGN) said Friday that a study evaluating its Sensipar drug for effectiveness in reducing the risk of mortality and cardiovascular events in patients suffering from chronic kidney disease failed to meet its primary endpoint. Sensipar--which is marketed as Mimpara in Europe--was first approved in 2004 to treat thyroid problems in patients with kidney disease and cancer. The company recorded $808 million in global sales of the drug last year. Amgen said Friday it undertook the Phase 3 trial of Sensipar to discover whether the drug could positively impact the high rates of mortality and incidences like heart failure experienced by patients with chronic kidney disease that are receiving dialysis. Results, however, were not statistically significant, Amgen said. The company noted analyses from the study are ongoing and will be submitted for presentation at a major medical meeting later this year. Amgen, the biggest stand-alone biotechnology company, has been pursuing deals to bolster its research-and-development pipeline as sales growth slows for older drugs. Shares were recently off 26 cents to $68.84. Write to Mia Lamar at mia.lamar@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
08/24/201620:10:00FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24/201619:20:00FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24/201618:03:00Amgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) N...
08/22/201609:00:00New Data Add To Understanding Of Repatha® (Evolocumab) In Multiple...
08/22/201608:50:00Eli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/19/201616:14:16Current Report Filing (8-k)
08/11/201617:29:34Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)
08/11/201606:06:00Free Writing Prospectus - Filing Under Securities Act Rules 163/433...
08/10/201608:27:19Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
08/06/201603:03:00AbbVie Sues Amgen Over Humira -- WSJ
08/05/201616:57:00AbbVie Files Patent Suit Over Amgen's Copy of Humira -- Update
08/05/201614:50:00AbbVie Sues Amgen Over Humira
08/05/201614:33:00AbbVie Files Patent Suit Over Amgen's Copy of Humira
08/02/201619:30:00CVS Drops Coverage of 2 Branded Biotech Drugs in Favor of Copies
08/02/201618:47:00CVS Drops Coverage of 2 Branded Biotech Drugs in Favor of Copies
08/02/201610:28:00Advaxis Shares Higher on Collaboration Deal With Amgen
08/02/201608:00:00Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration
07/29/201616:50:00Quarterly Report (10-q)
07/28/201609:42:00U.S. Hot Stocks: Hot Stocks to Watch
07/27/201618:55:00Amgen Profit Rises 13%, 2016 Outlook Raised -- Update

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad